Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind, placebo-controlled, dose-escalation study of BAY 3389934 in healthy Japanese participants
jRCT2071250068Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY3389934 in disseminated intravascular coagulation (DIC) (3 arms), sponsored by Bayer. Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs). Started Sep 2025; status: active, not recruiting.
02
Drugs
BAY3389934
03
Conditions
disseminated intravascular coagulation (DIC)
Beyond the preview
Go deeper on jRCT2071250068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250068.